Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces its trading update for the quarter ended 31 March 2013.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, of ‘de Groep’), het toonaangevende internationale bedrijf voor stamcelopslag en de grootste familiestamcelbank in Europa, publiceert de trading update over het kwartaal eindigend op 31 maart 2013.
A 4-year-old boy was treated for Blackfan-Diamond anaemia (BDA) with a stem cell transplant from his sister’s umbilical cord blood. The transplant was performed on April 25 at the Hospital del Niño Jesús in Madrid, one of the most important paediatric hospitals in Spain. It is the first transplant performed in this country to treat BDA with a cryo-preserved sample from a family bank, in this case, the leading Family Stem Cell Bank in Spain, Crio-Cord, a subsidiary of the Cryo-Save Group. This treatment was provided thanks to the Cryo-Save Cost Free Donation Program, which provides free storage of the umbilical cord blood and cord tissue stem cells for families who have a family member diagnosed with a disease treatable with stem cells.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that Mr Arnoud van Tulder, Chief Executive Officer, purchased 4,752 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €1.24 on Wednesday 10 April 2013.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that Mr Johan Goossens, Chairman, purchased 100,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price range between €1.19 and €1.24 on Friday 5 April and on Monday 8 April 2013.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2012.
Zutphen, The Netherlands, 19 March 2013
A large enough number of stem cells are needed to ensure the success of a cord blood transplant. However, the quantity of stem cells isolated from umbilical cord blood is not always sufficient to meet that requirement. Researchers from the Etablissement Français du Sang, Aquitaine-Limousin (France) have established a method to multiply cord blood stem cells to required quantity levels. In the current study Dr. Ivanovic and co-workers (Etablissement Français du Sang Aquitaine-Limousin) and a team of Cryo-Save researchers have demonstrated that these cultured stem cells can be frozen and thawed without negatively affecting the quality of the stem cells. An important step towards successful stem cell transplants in patients for whom too few stem cells are available.
Cryo-Save announced the appointment today of Ms. Evi Mattil as Chief Commercial Officer (CCO). She will be responsible for sales, marketing and communications worldwide. Ms. Mattil will be based at the company’s headquarter in Zurich. With more than 225,000 stem cell samples from umbilical cord blood and umbilical cord tissue, Cryo-Save is the largest family stem cell bank in Europe.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has commenced a new tranche of its share buyback programme.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has completed the tranche of its share buyback programme as announced on 30 January 2013.